- Home
- TXMD vs MBRX Comparison
TXMD vs MBRX Comparison
Compare TXMD & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- MBRX
- Stock Information
- Founded
- TXMD 2008
- MBRX 2015
- Country
- TXMD United States
- MBRX United States
- Employees
- TXMD N/A
- MBRX N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- MBRX Health Care
- Exchange
- TXMD Nasdaq
- MBRX Nasdaq
- Market Cap
- TXMD 13.5M
- MBRX 12.9M
- IPO Year
- TXMD N/A
- MBRX 2016
- Fundamental
- Price
- TXMD $1.17
- MBRX $0.55
- Analyst Decision
- TXMD
- MBRX Strong Buy
- Analyst Count
- TXMD 0
- MBRX 3
- Target Price
- TXMD N/A
- MBRX $5.33
- AVG Volume (30 Days)
- TXMD 35.2K
- MBRX 11.8M
- Earning Date
- TXMD 08-11-2025
- MBRX 08-13-2025
- Dividend Yield
- TXMD N/A
- MBRX N/A
- EPS Growth
- TXMD N/A
- MBRX N/A
- EPS
- TXMD N/A
- MBRX N/A
- Revenue
- TXMD $1,841,000.00
- MBRX N/A
- Revenue This Year
- TXMD $427.09
- MBRX N/A
- Revenue Next Year
- TXMD N/A
- MBRX N/A
- P/E Ratio
- TXMD N/A
- MBRX N/A
- Revenue Growth
- TXMD 53.55
- MBRX N/A
- 52 Week Low
- TXMD $0.70
- MBRX $0.25
- 52 Week High
- TXMD $2.44
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- TXMD 47.76
- MBRX 51.51
- Support Level
- TXMD $1.13
- MBRX $0.33
- Resistance Level
- TXMD $1.24
- MBRX $0.70
- Average True Range (ATR)
- TXMD 0.09
- MBRX 0.07
- MACD
- TXMD 0.01
- MBRX 0.04
- Stochastic Oscillator
- TXMD 73.12
- MBRX 66.24
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.